Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.

Vaccitech, a UK-based developer of vaccines for infectious diseases and cancer spun out of University of Oxford, filed for an initial public offering in the US on Friday.
Financial terms have not yet been set and Vaccitech has used a placeholder $100m target in its draft prospectus. The spinout is looking to list on the Nasdaq Global Market and is seeking a valuation of around $700m, according to the Wall Street Journal.
Founded in 2016, Vaccitech originally…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in